"Regulatory reviews are ongoing in over 40 countries" and "we plan to submit Foundayo in the U.S. for type 2 diabetes later this quarter" (Chairman & CEO Ricks). "Revenue grew 56% compared to Q1 2025" ...

The unchanged US$9.88 fair value estimate for LifeMD keeps the core price target steady, even as model inputs see only marginal tweaks. That stability lines up with recent analyst debate around Q4 ...

The Dow Jones Industrial Average jumped more than 700 points to close at 49,652, powered by gains in industrial and healthcare stocks despite weakness in mega-cap tech. Caterpillar and Eli Lilly ...

A simple outpatient procedure currently used for type 2 diabetes patients in Europe can help those on Eli Lilly’s obesity ...

AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Novo Nordisk A/S upgraded to Hold as FDA tightens compounded GLP-1s;Hims & Hers Health, Inc. stays Buy. Click for this NVO ...

With an uptick and increasingly even spread of capital across the space, the BIA’s Martin Turner is optimistic for British biotech’s future.

AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteer ...

The three funds on this list provide access to VIX futures contracts that aim to provide greater returns as market volatility ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Shares of Veradermics Inc. spiked as the first top-line readout from its registrational program for VDPHL-01 showed the oral, extended-release version of minoxidil surpassed expectations in men with ...